To Book an Appointment

COVID-19 Cicada Variant (BA.3.2): Symptoms, Transmission, Vaccines, and Prevention

By Dr. Meenakshi Jain in Internal Medicine

Mar 31 , 2026

As COVID-19 continues to evolve, scientists have identified a new subvariant, the COVID-19 Cicada variant (BA.3.2). This variant has been detected in multiple countries and is currently classified as a Variant Under Monitoring (VUM).

Known for its high number of mutations in the spike protein, BA.3.2 is being closely studied for transmissibility, vaccine escape potential, and reinfection risk. Understanding the Cicada variant is critical for staying safe during ongoing COVID waves.

What Is the COVID-19 Cicada Variant (BA.3.2)?

The Cicada variant (BA.3.2) is a sublineage of the Omicron SARS-CoV-2 variants. It carries numerous mutations in the spike protein, the key structure that allows the virus to infect human cells.

Experts are monitoring BA.3.2 because these mutations may influence:

Immune escape from previous infection or vaccination
Vaccine effectiveness
Transmissibility

Despite these mutations, current data shows that BA.3.2 does not cause significantly more severe disease than earlier Omicron variants.

Why It’s Called the “Cicada” Variant

The nickname “Cicada” reflects the variant’s delayed emergence. Much like cicada insects that appear after years underground, BA.3.2 emerged after circulating quietly in older virus lineages. This periodic re-emergence caught the attention of scientists and media alike.

Symptoms of the COVID-19 Cicada Variant

Current evidence shows that BA.3.2 symptoms are similar to those of other Omicron subvariants, mainly affecting the upper respiratory system. Common symptoms include:

Fever or chills
Cough
Sore throat
Runny or blocked nose
Fatigue and body aches
Headache
Loss of taste or smell (less common than previous variants)

How Contagious Is the Cicada Variant?

BA.3.2 primarily spreads through respiratory droplets and aerosols, as do other COVID-19 variants. Early reports indicate moderate transmissibility, but not necessarily higher than dominant Omicron strains.

Vaccine Effectiveness Against BA.3.2

Current vaccines remain highly effective at preventing severe illness, hospitalisation, and death from BA.3.2.

Bivalent and updated COVID boosters improve protection against this variant
Vaccines reduce viral load and transmission risk
Antiviral treatments (e.g., Paxlovid) remain effective for high-risk patients

Prevention and Safety Measures

Even with new variants like BA.3.2, basic COVID-19 prevention strategies are still effective:

Stay up to date with vaccinations and boosters
Wear high-filtration masks (N95/KF94) in crowded indoor spaces
Maintain hand hygiene and surface cleaning
Improve indoor ventilation
Stay home if symptomatic or after exposure

When to Seek Medical Care

Seek immediate care if you experience:

Shortness of breath
Chest pain or pressure
Confusion or drowsiness
Severe or worsening symptoms

High-risk individuals should consult healthcare providers early for antiviral therapy.

Conclusion

The COVID-19 Cicada variant (BA.3.2) is a monitored subvariant of SARS-CoV-2 with multiple mutations in the spike protein. Vaccines, boosters, masks, and antiviral therapies remain the most effective tools for protection.

Staying informed, practising prevention, and seeking early treatment are essential strategies for navigating the evolving COVID-19 landscape in 2026.